Kelly K. Hunt – författare

This issue of Surgical Oncology Clinics of North America, guest edited by Dr. Kelly Hunt, is devoted to Breast Cancer. Dr. Hunt has assembled expert authors to review the following topics: Tomosynthesis in breast cancer imaging: how does it fit into preoperative evaluation and surveillance?; Lobular breast cancer: different disease, different algorithms?; Hypofractionated radiation therapy in breast conserving therapy; Oncoplastic breast reconstruction: should all patients be considered?; Neoadjuvant endocrine therapy: who benefits most?; Breast cancer disparities: how can we leverage genomics to improve outcomes?; Anatomy and breast cancer staging: is it still relevant?; When does atypical ductal hyperplasia require surgical intervention?; Surgical intervention for lymphedema; Are there alternative strategies in the local management of DCIS?; Genetic testing and genetic counseling: what is standard of care?; Molecular subtypes and local-regional control of breast cancer; Intraoperative margin assessment in breast cancer management; Triple negative breast cancer: who should receive neoadjuvant chemotherapy?; and more!

I am honored to write the Foreword for this first volume of the M. D. Anderson Cancer Care series, because I believe the book represents a milestone not only for M. D. Anderson but also for cancer specialists everywhere. All of us, whether we work in academic medical institu­ tions, medical school hospitals, community hospitals, oncology clinics, or solo practice, have seen remarkable changes in our practice over the recent decades. We know that breast cancer patients live longer, feel better, and look better than ever before, and they face this dreaded disease with more optimism than ever before. Each of us deserves to be proud of this progress. Though I am now primarily a laboratory scientist and admin­ istrator, I am proud of my own work on factors that control the growth of tumor cells, most prominently through regulation of EGF receptors and HER-2/neu, and the promise that work holds for women who have breast cancer. The authors represented in this volume have made important contri­ butions to breast cancer care. Likewise, every reader of this book has and will continue to make critical contributions to the health of women with breast cancer. I would like to express the hope here that each of us takes the opportunity to step outside our subspecialties-surgeon, internist, radiation oncologist, pathologist, radiologist, laboratory scientist-and learn how we can better integrate our work with that of other specialists.

This second edition of Breast Cancer continues the tradition of the M. D. Anderson Cancer Care Series. The book is oriented towards the needs of clinicians who manage breast cancer at every stage of the disease. Ch- ters are written by experts with a strong knowledge of research findings who also are active in the clinic and understand the practical needs of the patient and her physician. Multidisciplinary care is a popular term today, but such care has been practiced at M. D. Anderson Cancer Center for decades. The physicians who assembled this book are experienced practitioners of multidiscip- nary care. The authors of each chapter carry out their clinical activities at our Nellie B. Connally Breast Center, where they collaborate in providing complete patient care services at a single site. The chapters start, logically, with prevention of breast cancer and p- sonalized risk assessment, including genetics. These topics are followed by chapters on early detection, with emphasis on a variety of sophis- cated imaging techniques and sampling of tissue. The various surgical options, including reconstruction, are thoroughly presented. Before me- cal oncology is introduced there are chapters dealing with the growing use of markers to predict prognosis and to select hormonal or chemoth- apy treatments that are likely to succeed. The book concludes with issues related to survivorship, including re-entering social and job-related acti- ties and dealing with questions related to sexuality and reproduction.

This second edition of Breast Cancer continues the tradition of the M. D. Anderson Cancer Care Series. The book is oriented towards the needs of clinicians who manage breast cancer at every stage of the disease. Ch- ters are written by experts with a strong knowledge of research findings who also are active in the clinic and understand the practical needs of the patient and her physician. Multidisciplinary care is a popular term today, but such care has been practiced at M. D. Anderson Cancer Center for decades. The physicians who assembled this book are experienced practitioners of multidiscip- nary care. The authors of each chapter carry out their clinical activities at our Nellie B. Connally Breast Center, where they collaborate in providing complete patient care services at a single site. The chapters start, logically, with prevention of breast cancer and p- sonalized risk assessment, including genetics. These topics are followed by chapters on early detection, with emphasis on a variety of sophis- cated imaging techniques and sampling of tissue. The various surgical options, including reconstruction, are thoroughly presented. Before me- cal oncology is introduced there are chapters dealing with the growing use of markers to predict prognosis and to select hormonal or chemoth- apy treatments that are likely to succeed. The book concludes with issues related to survivorship, including re-entering social and job-related acti- ties and dealing with questions related to sexuality and reproduction.

Selected as a Doody’s Essential Title for 2025​!Presented by the American College of Surgeons and the Alliance for Clinical Trials in Oncology, the first comprehensive, evidence-based examination of cancer surgery techniques as standards distills the well-defined protocols and techniques that are critical to achieve optimal outcomes in a cancer operation. This unique, one of a kind collaboration between the American College of Surgeons and the Alliance for Clinical Trials in Oncology focuses on best practices and state-of-the-art methodologies. Operative Standards for Cancer Surgery clearly describes the surgical activities that occur between skin incision and skin closure that directly affect cancer outcomes.Key FeaturesQuickly grasp the proper technical elements of a cancer operation through clear, practical text and more than 120 illustrations. Benefit from careful analysis of the best evidence available in the literature, gathered here to create the highest quality standards in four key disease sites: breast, colon, lung, and pancreas. Learn from experts drawn from diverse groups including the American College of Surgeons, the Alliance for Clinical Trials in Oncology, the National Cancer Institute Cooperative Groups, and the Commission on Cancer, as well as national societies and organizations with an interest in these four cancer types. Now with the print edition, enjoy the bundled interactive eBook edition, offering tablet, smartphone, or online access to: Complete content with enhanced navigation . Powerful search tools and smart navigation cross-links that pull results from content in the book, your notes, and even the web. Cross-linked pages, references, and more for easy navigation. Highlighting tool for easier reference of key content throughout the text. Ability to take and share notes with friends and colleagues. Quick reference tabbing to save your favorite content for future use.

The possibility of treating cancer, a disease defined by genetic defects, by introducing genes targeting these very alterations has led to an immense interest in gene therapy for cancer. Although incremental successes have been realized, enthusiasm for gene therapy has declined due to an increasing number of obstacles. These obstacles include vector systems that do not reach systemic metastases, therapeutic genes with redundant mec- nisms allowing for cellular resistance, and toxicities in clinical trials leading to premature closure of these studies. Different tactics to overcome or circumvent these obstacles have catalyzed the development of a wide range of gene therapy approaches. Thus far, almost two-thirds of gene therapy trials have focused on cancer. This reflects the concept that gene therapy approaches for the treatment of cancer do not necessarily require long-term expression of the gene as is necessary for the treatment of primary genetic defects like hemophilia or juvenile diabetes. Unlike the treatment of genetic defects, where expr- sion of the corrected gene needs to be strong, permanent and, sometimes regulated, tactics to treat tumors can be based on temporary and locally limited effects. In addition, cancer cells have different properties than normal cells and this allows for targeting gene therapy to specific cells, a major advantage over current antitumor therapies, which are also toxic to normal cells and tissues.

The possibility of treating cancer, a disease defined by genetic defects, by introducing genes targeting these very alterations has led to an immense interest in gene therapy for cancer. Although incremental successes have been realized, enthusiasm for gene therapy has declined due to an increasing number of obstacles. These obstacles include vector systems that do not reach systemic metastases, therapeutic genes with redundant mec- nisms allowing for cellular resistance, and toxicities in clinical trials leading to premature closure of these studies. Different tactics to overcome or circumvent these obstacles have catalyzed the development of a wide range of gene therapy approaches. Thus far, almost two-thirds of gene therapy trials have focused on cancer. This reflects the concept that gene therapy approaches for the treatment of cancer do not necessarily require long-term expression of the gene as is necessary for the treatment of primary genetic defects like hemophilia or juvenile diabetes. Unlike the treatment of genetic defects, where expr- sion of the corrected gene needs to be strong, permanent and, sometimes regulated, tactics to treat tumors can be based on temporary and locally limited effects. In addition, cancer cells have different properties than normal cells and this allows for targeting gene therapy to specific cells, a major advantage over current antitumor therapies, which are also toxic to normal cells and tissues.